Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-374-125"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-374-125"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-374-2502
lpv:speaker	lp:Marie-Thérèse Sanchez-schmid2
lpv:spokenAs	substitute; Delegation for relations with the Mashreq countries (2009-09-16--2014-06-30)3,3 substitute; REGI (2012-01-19--2014-06-30)3,3 member; CULT (2012-01-19--2014-06-30)3,3 substitute; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2009-09-16--2014-06-30)3,3 unknown; Union pour un Mouvement Populaire (2009-07-14--2014-06-30)3,3 member; EPP (2009-07-14--2014-06-30)3,3 substitute; Delegation to the ACP-EU Joint Parliamentary Assembly (2011-05-03--2014-06-30)3,3 member; Delegation for relations with South Africa (2009-09-16--2014-06-30)3,3
lpv:translated text	"Following the scandal surrounding Mediator, which was potentially implicated in more than 500 deaths in France, the European Union carried out ‘stress tests’ on its pharmacovigilance legislation in order to ensure that it was well suited to such situations. The Commission has brought forward new measures that will enhance patient safety by reforming the method for detecting any undesirable effects of an authorised medicine, refining risk assessment and improving responses to risk. I therefore voted for this report, which improves the Commission’s proposal by enhancing the coordinating role of the European Medicines Agency and the detection of any signs of risk concerning a medicinal product."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph